Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

The impact of DAMP-mediated inflammation in severe COVID-19 and related disorders

Upasana Parthasarathy\textsuperscript{a}, Roberta Martinelli\textsuperscript{a}, Elisabeth H. Vollmann\textsuperscript{b}, Katharine Best\textsuperscript{a}, Alex G. Therien\textsuperscript{a,}\textsuperscript{*}

\textsuperscript{a} Exploratory Science Center, MRL, Merck & Co., Inc, Cambridge, MA, USA
\textsuperscript{b} MRL, Merck & Co., Inc, Boston, MA, USA

ARTICLE INFO

Keywords:
DAMP
TLR/PRR
Siglecs
CD24
CD24Fc
ARDS
HMGB1
Neutrophils
Endothelial Dysfunction
Hypercoagulation

ABSTRACT

The host response to SARS-CoV-2, the virus that causes COVID-19, is highly heterogeneous, ranging from mild/asymptomatic to severe. The moderate to severe forms of COVID-19 often require hospitalization, are associated with a high rate of mortality, and appear to be caused by an inappropriately exaggerated inflammatory response to the virus. Emerging data confirm the involvement of both innate and adaptive immune pathways both in protection from SARS-CoV-2, and in driving the pathology of severe COVID-19. In particular, innate immune cells including neutrophils appear to be key players in the inflammation that causes the vicious cycle of damage and inflammation that underlies the symptomatology of severe COVID-19. Several recent studies support a link between damage and inflammation, with damage-associated molecular patterns (DAMPs) playing a key role in the pathology of severe COVID-19. In this review, we put into perspective the role of DAMPs and of components of the DAMP-signaling cascade, including Siglecs and their cognate ligands CD24 and CD52, in COVID-19. Further, we review clinical data on proposed therapeutics targeting DAMP pathways to treat SARS-CoV-2 infection and the regulation of these signaling cascades in COVID-19. We also discuss the potential impact of DAMP-mediated inflammation in other indications related to COVID-19, such as ARDS, endothelial dysfunction, hypercoagulation, and sepsis.

1. Introduction

The ongoing COVID-19 pandemic has had immeasurable impact on human lives globally since the disease was first described in December 2019, in Wuhan, China. As of September 2021, over 200 million documented cases of COVID-19 and over 4 million fatalities have been reported around the world [1]. COVID-19 is caused by a novel coronavirus, SARS-CoV-2, belonging to the genus Betacoronavirus, which also includes the common cold viruses HKU1, NL63, OC43, as well as the more pathogenic viruses SARS-CoV and MERS-CoV. The disease has highly heterogeneous effects on patients, ranging from asymptomatic infection to severe multi-organ damage leading to death. Patients at risk of developing severe disease include the elderly, and patients with chronic health conditions like obesity and cardiovascular disease [2]. Beyond the acute effects of SARS-CoV-2 infection, long-lasting symptoms are common in convalescent patients that survive the initial infection, a syndrome known as “long COVID” or post-acute sequelae of COVID-19 (PASC) [3-5].

The disruptive impact of the COVID-19 pandemic has triggered an unprecedented global wave of scientific innovation that has resulted in the rapid discovery and development of multiple vaccines and therapeutics to prevent and treat COVID-19. The first vaccine for the prevention of COVID-19, Gam-COVID-Vac, was approved for emergency use by the Russian Ministry of Health in August 2020, just 5 months after the disease was declared a pandemic. The mRNA-based vaccine from Pfizer, tozinameran, earned the first emergency use approval for a
COVID-19 vaccine in the west, specifically in the UK, in December 2020. Since then, over a dozen different vaccines have been approved for clinical use in almost 200 countries [6-8]. In addition to vaccines, a handful of therapeutics have been approved, fully or for emergency use, for treatment of COVID-19 in different jurisdictions: the broad anti-inflammatory dexamethasone; the antivirals remdesivir and favipiravir; the anti-SARS-CoV-2 antibodies bamlanivimab/etesevimab, casirivimab/imdevimab, sotrovimab, and regdanavab; the anti-IL-6 antibody tocilizumab; and convalescent plasma [9,10]. Dozens of additional vaccines and therapies are in late-stage clinical development, promising to add to the armamentarium of available remedies for this devastating disease.

In addition to driving the development of new vaccines and therapeutics, the ongoing scientific surge has enabled a deep, if still incomplete, understanding of SARS-CoV-2 infection and COVID-19 pathology. Within weeks of the discovery of SARS-CoV-2, it was demonstrated that the key host receptor for the virus is ACE2 and that the virus binds to this protein on the surface of human cells via its spike glycoprotein [11]. Viral attachment to host cells leads to internalization of the virus, viral replication, cell death, and release of nascent virions that can infect neighboring cells, perpetuating the replication cycle. While other potential receptors have been described for SARS-CoV-2, ACE2 appears to be the primary receptor, and cells that do not express ACE2 are generally resistant to infection [12]. This is consistent with the observation that the virus primarily infects epithelial cells of the lung and gut which express ACE2, although it has also been suggested that SARS-CoV-2 can infect other cell types within the body, including cardiomyocytes, neurons, endothelial cells, and some leukocytes [13-19].

In most patients, infection with SARS-CoV-2 is associated with a rapid, often pre-symptomatic, increase in viral load, triggering an immune response that effectively clears the virus within days and is associated with relatively mild symptoms that resemble the flu – mild respiratory distress, fever, and body aches. In other patients, in particular those with underlying risk factors like age and comorbidities, the disease can progress to more severe symptoms including respiratory failure, and in some cases death [20,21]. Severe COVID-19 is thought to result from a harmful self-perpetuating cycle of hyperinflammation and tissue/cellular damage due to an inappropriately extreme immune response, sometimes associated with cytokine storm and/or ARDS. Much of the work seeking to characterize COVID-19 pathology has focused on the adaptive immune response which is undoubtedly important in pathogen clearance and in establishing immune memory, as demonstrated by the high level of efficacy achieved with COVID-19 vaccines. However, the innate immune response also plays an important role in perpetuating the hyper-inflamed state that contributes to severe forms of COVID-19. Recent data have implicated monocytes, neutrophils, and other myeloid cells, in COVID-19 pathology. In this review, we discuss this expanding appreciation for the role played by the innate immune system in moderate to severe forms of COVID-19, and highlight evidence to support that damage-associated molecular patterns (DAMPs) may be key players in the cycle of damage and inflammation that underlies severe forms of the disease. Furthermore, we suggest that our evolving understanding of COVID-19 pathology will inform future treatment options not only for COVID-19 but also for other diseases, infectious or not, which exhibit similar mechanisms of disease.

2. Immune mechanisms in COVID-19

SARS-CoV-2 is a respiratory virus whose human-to-human transmission is predominantly mediated through droplets and aerosols that are formed during speaking, coughing, and sneezing. Thus, mucosal tissues of the mouth and respiratory tract are among the first to come into contact with the virus. These tissues are also the most vulnerable for viral infection owing to their high expression of ACE2. Infection of the host cells leads to viral replication and release of viral particles associated with cell and tissue damage and release of DAMPs. In severe disease, it is thought that these molecules trigger an inflammatory immune cascade characterized by a vicious cycle of immune cell activation and further loss of tissue integrity.

Patients with severe COVID-19 present with inflammatory foci in the lungs that are detectable macroscopically by X-ray. In these patients, SARS-CoV-2 has typically infected the ACE2-expressing epithelial cells in the lower airway, triggering an immune response that ultimately leads to hospitalization, and possibly to the need for intensive care and intubation [22]. In addition to respiratory symptoms, COVID-19 patients can also develop thrombotic complications, pulmonary embolism and problems associated with increased coagulation, reminiscent of disseminated intravascular coagulation observed in sepsis patients. Patients exhibit elevated D-dimer levels and widespread alveolar capillary microthrombi [23-25], altered platelet-immune cell interactions [26,27] and the presence of megakaryocytes in affected lungs. The clinical course of COVID-19 is driven by the host immune response, which can range from appropriate and protective, to uncontrolled and highly dysfunctional, and everywhere in between.

The normal and protective host response to SARS-CoV-2 begins with recognition of pathogen-associated molecular patterns (PAMPs), such as viral single-stranded RNA, by innate immune cells through pattern recognition receptors (PRRs) including toll-like receptors (TLRs), C-type lectin receptors (CLRs), NOD-like receptors (NLRs). RIG-I-like receptors (RLRs) and melanoma differentiation-associated protein 5 (MDA5). This leads to activation of immune cells, secretion of pro-inflammatory cytokines and establishment of a chemokine gradient to recruit additional innate and adaptive immune cells to the site of inflammation [28]. Similarly, activation of resident myeloid cells leads to their mobilization and migration to the draining lymph node where they present viral antigens to T and B cells, orchestrating the protective adaptive immune response, including the establishment of immune memory. If the immune response is successful, patients typically recover within 7 to 14 days post-infection. The protective nature of an appropriate immune response to SARS-CoV-2 is exemplified in vaccinated individuals who have circulating neutralizing antibodies and memory lymphocytes specific for the viral capsid protein which can fend off infection, or at least lessen the severity and duration of disease.

In a subset of patients, however, the adaptive immune response fails to clear the virus and eventuallyeters out due to T cell exhaustion and an inadequate B cells/antibody (humoral) response [29]. Persistence of the viral infection leads to continued activation of the innate immune system and production of pro-inflammatory cytokines [30], which can lead to systemic vascular inflammation and aberrant coagulation, among other non-pulmonary symptoms. A reduced type I interferon (IFN-I) response may contribute to the inability of the host to clear the virus, leading to the uncontrolled inflammatory response that drives severe COVID-19 [31,32], consistent with the higher levels of autoimmunecytokines specific for type I IFNs observed in these patients [33,34]. However, the role of type I interferon (IFN-I) response in severe COVID-19 patients still remains unclear since some reports show a robust IFN-I response in severe COVID-19 [35-37].

3. Innate immunity in COVID-19

Much of the available data on the role of the adaptive and innate immune responses in COVID-19 has been gleaned from patient cohort studies utilizing state-of-the-art multi-omics approaches [30,38-43]. Initial immunophenotyping studies indicated lymphopenia and increased abundance of neutrophils in severe COVID-19 [44-46]. Deeper bulk and single-cell transcriptomics approaches identified increased expansion of plasmablasts, megakaryocytes and increased erythropoiesis [39]; basophil depletion, alterations in non-neutrophil myeloid cells including monocytes, macrophages, dendritic cells (DCs), and B/T cell phenotypes [38,41]; and increase in inflammatory macrophages and altered epithelial-immune cell interactions [43] in severe patients. Overall, these data paint a picture wherein the adaptive immune
response driven by CD4+CD8+ T cells and antibody production is crucial in controlling SARS-CoV-2 infection, whereas severe disease seems to result in part from an altered/dysfunctional and insufficient adaptive response. In such cases, the innate immune response, normally the first line of defense in infection, plays an outsized role, perhaps as a compensatory mechanism for an inadequate adaptive response.

In line with this, early studies into the pathology of COVID-19 showed a systemic increase of a variety of pro-inflammatory cytokines and chemokines (including IL-6, IL-7, IL-10, TNF-α, and IP10) [47]. Furthermore, mononuclear phagocytes are elevated in bronchoalveolar fluid (BALF) of severe COVID-19 patients, pointing to activation and dysregulation of monocytes and macrophages in COVID-19-associated hyperinflammation [48,49]. Peripheral blood is enriched in pro-inflammatory CD14highCD16high monocytes, and has abnormally low levels of non-classical CD14dimCD16high monocytes, in COVID-19 patients confined to intensive care [30,50–52]. In addition to this inflammatory dysfunction, altered host metabolic processes are observed in severe COVID-19. Specifically, a recent study has shown that increasing disease severity in COVID-19 correlates with differential abundance and metabolic programming of hyperactive T cell sub-populations and two metabolically distinct monocyte subsets. In addition, results from this study have identified acetocetate and α-ketobutyrate as markers for predicting disease outcome in individuals diagnosed with COVID-19 [53]. Further, the products of purine metabolism, nicotinate and nicotinamide metabolism, tryptophan metabolism, TCA cycle, and arginine metabolism are all also associated with higher disease severity [54–57].

Beyond the studies outlined above, most early assessments of the immune response to SARS-CoV-2 largely overlooked innate immune cells - in particular neutrophils - possibly due to technical challenges (for instance, the study of neutrophils requires freshly drawn blood) as well as to the justified race to study the adaptive immune response with the goal of developing vaccines and identifying neutralizing antibodies as potential treatments for patients. However, evidence from recent studies has begun to implicate neutrophils and neutrophil extracellular trap (NET) formation (NETosis) in the pathophysiology of inflammation, coagulopathy, organ damage, and immunothrombosis associated with severe COVID-19 [58–62]. Indeed, activated neutrophils - rather than platelets - appear to be the drivers of coagulation, through a mechanism mediated by NETs and reminiscent of sepsis [63,64]. As the primary innate immune effectors, it is not surprising that neutrophils also play a critical role in ARDS, characteristic of COVID-19. Neutrophils are armed with an arsenal of microbialidal effectors, including cell damaging reactive oxygen species (ROS) generated by the Rac2/NADPH oxidase complex [65,66]. Additionally, they possess a wealth of anti-microbial enzymes (e.g. neutrophil elastase, cathespins-G, myeloid peroxidase, matrix metalloproteinases, and peptides (e.g. LL-37, bactericidal permeability increasing protein (BPI)) stored in cytoplasmic granules [65,66]. While these are normally deployed through local degranulation (DG) and respiratory burst (RB) within phagosomes to destroy an internalized pathogen, the excessive DG/RB that occurs the context of inflammatory diseases leads to release of these mediators into the extracellular space, where they can cause collateral damage to host tissues, including the lungs, blood vessels, and others [67–76].

In addition to their more classical functionalities, neutrophils can also cause damage through NETosis, a recently described alternative effector modality in these cells. NETosis involves the progressive re-organization and secretion of nuclear material, leading to the formation of NETs made of DNA fibers that ensnare pathogens [77–81]. While NETosis likely evolved as a protective mechanism, NETs have also been associated with several pathological conditions ranging from infectious diseases to inflammatory disorders including systemic lupus erythematosus, rheumatoid arthritis, small vessel vasculitis, gout, and cardiovascular disease. For instance, a randomized clinical trial identified an association between markers of NETs and poor outcome in community-acquired pneumonia [82]. Overall, it is thought that NETs are involved in mediating the crosstalk between cells of the innate and adaptive immune systems and can induce localized tissue damage independent of the infecting organism, thus perpetuating a vicious circle of damage and inflammation. Furthermore, NETs are a driver of coagulation in bacterial sepsis, endocarditis, and pneumonia [83], owing to their ability to facilitate thrombus formation by activated platelets.

Recent data show that NETs may play a role in the pathology of COVID-19. Indeed, treatment of healthy neutrophils with serum from COVID-19 patients triggered the release of NETs, and SARS-CoV-2 has been shown to stimulate neutrophils to release NETs via interactions with ACE2 [58,59]. Different constituents of NETs along with other factors such as oxidative stress, excessive immune signaling, and increased alveolar epithelial cell necrosis contribute to release of endogenous DAMPs, severe hypoxia, and eventually ARDS, in patients with severe COVID-19 [84–89]. While DAMPs normally act as key bridging molecules between immune and non-immune cells during the cycle of tissue injury and immune resolution, under pathological conditions, including in COVID-19, they can amplify the innate and adaptive immune responses by directly activating various cell subsets, leading to further inflammation and tissue/cell damage.

4. DAMP signaling in COVID-19

Similar to PAMPs, DAMPs act through various cell-surface and intracellular PRRs such as membrane-bound TLRs and CLRs; cytoplasmic NLRs, RLRs, MDA5, cyclic GMP–AMP synthase (cGAS), absent in melanoma 2 (AIM2), or through non-classical transmembrane proteins such as receptor for advanced glycation end products (RAGE), triggering receptors expressed on myeloid cells (TREM), G-protein-coupled receptors (GPCRs), transient receptor potential (TRP) and P2X7 receptor (P2X7R) channels [28]. DAMP-PRR signaling triggers the activation of canonical myeloid differentiation primary response gene 88 (MyD88) cascade proteins including IL-1 receptor-associated kinases (IRAKs), transforming growth factor-β activated kinases (TAK), TAK binding proteins (TABs), mitogen-activated protein kinases (MAPKs), and IκB kinase (IKK) isoforms. This results in translocation of NF-kB to the nucleus, transcription of various pro-inflammatory mediators, and regulation of several cellular processes including apoptosis, proliferation, adhesion, and angiogenesis [90,91]. PRR-mediated activation of NF-kB signaling also leads to transcriptional upregulation of intracellular inflammasome genes; DAMPs can bind to and activate NLRP3, leading to caspase-1 autoproteolysis and activation, and cleavage of pro-IL-1β and pro-IL-18 to their active forms, IL-1β and IL-18. Pro-inflammatory signaling by NLRP3 inflammasome results either in cellular death by pyroptosis or activation of downstream processes such as recruitment of immune cell populations, immune surveillance, and cell proliferation [92]. In this way, DAMP-mediated localized inflammatory cell death and signaling can further extend to the vasculature, leading to barrier disintegration and leakage of inflammatory mediators, thus triggering a cycle of cell injury, amplified inflammation, and dysregulation of cellular processes.

Recent plasma proteomic studies have revealed increases in DAMPs including circulating mitochondrial DNA, HMGB1 and S100 proteins in moderate to severe COVID-19 patients [40,42,47,90,93–96]. Based on their known pro-inflammatory effects, summarized above, high levels of circulating DAMPs are likely to play an exacerbative role in COVID-19. Indeed, it can be surmised that DAMPs play a critical role in driving the uncontrolled immune response associated with COVID-19, as demonstrated in part by the protective effects of Paquinimod, a specific inhibitor of S100A8/A9 which can reduce pathological inflammatory signaling by neutrophils and re-establish an optimal anti-viral response against COVID-19 [97]. In addition, increased HMGB1 in severe COVID-19 patients has been shown to promote ACE2 expression via the RAGE receptor in alveolar epithelial cells, thereby facilitating viral entry into cells [93]. In some instances, DAMPs may play a protective role in disease, such as in the case of elevated levels of alarmins such as S100A8

U. Parthasarathy et al.
Biochemical Pharmacology 195 (2022) 114847
and S100A9 that are correlated with an anti-viral immune responses [97,98]. Nevertheless, the totality of the data point toward a harmful role of DAMPs in COVID-19. This is further supported by studies implicating other components of DAMP-mediated signaling, including DAMP receptors, and associated signaling components, as discussed below.

5. Siglec signaling in COVID-19

The innate immune machinery has evolved to modulate PAMP/DAMP-PRR signaling pathways at transcriptional, post-transcriptional and post-translational levels [99,100]. For instance, phosphatases SHP-1 and SHP-2 mediate inhibition of PRR signaling by selectively dephosphorylating different components of NF-κB and MAPK pathways [101,102]. The sialic acid–binding immunoglobulin-like lectins (Siglecs) are one group of proteins that utilize SHP-1 to act as a checkpoint on the innate immune system. Indeed, the majority of Siglecs are primarily expressed on innate immune cells, and contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or ITIM-like regions in their intracellular domains, through which they suppress DAMP-mediated NF-κB signaling [103].

Results from recent studies highlight the potential significance of Siglecs in COVID-19 (Fig. 1). For instance, sialylated secreted glycoproteins from SARS-CoV-2 can bind to and activate host Siglecs thus downregulating the antiviral response [104]. Furthermore, SARS-CoV-2 viral spike proteins contain α2,6 and α2,3 linked sialic acids that enable their interaction with Siglec-1, Siglec-3, Siglec-9, and Siglec-10, facilitating their entry into host immune cells [19,105], a phenomenon which can be blocked with an anti-Siglec-1 monoclonal antibody [19] (Fig. 1A). On the other hand, Siglecs appear to play a protective role in the context of severe COVID-19 by tamping down the uncontrolled inflammation that drives pathology. For example, Siglec-9 agonist was found to be effective in inhibiting cellular activation and excessive NETosis in neutrophils from patients with COVID-19 [106] (Fig. 1B). This suggests an interplay between biological regulation of Siglecs and the cycle of injury perpetuated by aberrant NETosis and increased DAMPs such as HMGB1 and S100 proteins in severe COVID-19.

6. Regulation of DAMP-PRR-Siglec signaling cascade in COVID-19

Under homeostatic conditions, endogenous DAMPs signal via PRRs and non-PRRs to trigger downstream innate immune responses and production of pro-inflammatory cytokines through activation of either the NF-κB or NLRP3 inflammasome cascades [28]. Therefore, modulating the activity of DAMP ligands, receptors, and/or NF-κB/NLRP3 inflammasome signaling components, may be beneficial in various disease states, including severe COVID-19. One possible approach involves activation of the Siglecs, either directly, or through their cognate ligands CD24 and CD52. CD24 and CD52 are related proteins with similar

---

Fig. 1. Therapeutic targeting of Siglecs in COVID-19. (A) Viral capture and uptake by Siglec-1 on myeloid antigen presenting cells (APCs) leads to cytokine storm and viral propagation. Anti-Siglec-1 monoclonal antibodies (mAbs) can block uptake of SARS-CoV-2 and inhibit trans-infection of target cells expressing ACE2/TMPRSS2 [19]. (B) SARS-CoV-2 pathogen/damage-associated molecular pattern (PAMP and DAMP)-mediated pattern recognition receptor (PRR) stimulation leads to production of pro-inflammatory neutrophil extracellular traps (NETosis), that propagate the hyperinflammatory cascade in COVID-19. Synthetic Siglec-9 agonists can trigger clustering of Siglec-9 receptors on neutrophils and suppress NETosis and associated inflammation in COVID-19 [106]. (C) Association of CD24 or CD52 with Siglec-10 inhibits PAMP/DAMP-PRR-mediated inflammatory responses. CD24Fc and CD24 exosomes may act through Siglec stimulation to protect against severe COVID-19 [118,119]. Treatment with anti-human CD52 antibody is associated with mild COVID-19 symptoms and may also act through Siglec stimulation [116]. (D) Increased levels of neuraminidase 1 (Neu1) enzyme in severe COVID-19 may prevent protective Siglec activation through cleavage of sialic acid (SA) residues on CD24/CD52. Treatment with Neu inhibitors Oseltamivir or Zanamivir reduces SA shedding and neutrophil overactivation in COVID-19 patients [128].
CD24 has been shown to associate with Siglec-10 and downregulate HMGB1-mediated NF-κB inhibition, while soluble CD52 binding to Siglec-10 inhibits T cell receptor-associated kinase phosphorylation and T cell activation [109,110]. Interestingly, recent clinical data support a potential role for CD24 and CD52 in COVID-19 (Fig. 1C).

Alemtuzumab, an anti-human CD52 antibody, was designed to deplete CD52+ lymphocytes in lymphocyte-mediated diseases such as multiple sclerosis (MS) and graft-versus-host disease [111,112]. While patients treated with alemtuzumab have varying levels of immunodefiency and an increased risk of infection, case reports indicate that alemtuzumab-treated multiple sclerosis (MS) patients developed mild COVID-19 disease [113–117]. It has not been determined whether milder symptoms are due to CD52 depletion-induced immunosuppression or to Siglec-dependent down-regulation of inflammation. Given its role in inhibition of DAMP signaling and the increased levels of DAMPs in COVID-19, a targeted increase in CD52 signaling, perhaps through dosing of CD52 itself in some form, could be beneficial in the context of severe COVID-19. Indeed, such an approach was used recently with the related protein CD24. Results from an interim analysis of a Phase III clinical trial with CD24Fc, a protein consisting of two molecules of CD24 attached to a single human IgG1 Fc, showed a decreased risk of respiratory failure and death compared with the placebo group, in moderate to severe COVID-19 patients [118]. Another clinical study from the Tel-Aviv Sourasky Medical Center evaluated the efficacy of inhaled CD24-containing exosomes in patients with moderate/severe COVID-19 disease. The results showed that 29 out of 30 patients treated with this therapy fully recovered from disease within three to five days, although no placebo control arm was included in this study [119]. While both CD24 and CD52 drive inhibition of DAMP-mediated inflammation, existing literature suggests that these two proteins could be acting on different immune subsets - CD24 on myeloid populations [120–122] and CD52 on lymphocyte populations [110,123–125]. Overall, available clinical data are consistent with a protective effect of CD24 and CD52 in COVID-19, though additional studies are required to confirm these beneficial effects, and to better understand the mechanism of protection. Given the multiple known biological effects of CD24 and CD52 – including, but not limited to, activation of Siglecs - any beneficial effects of increasing CD24/CD52-mediated signaling in severe COVID-19 must be weighed against the potential harmful effects of targeting this complex biology.

The role of sialic acid residues in Siglec binding and activation could also be harnessed as a potential therapeutic approach in COVID-19 [126,127]. Neuraminidase (Neu) enzymes, which are expressed at higher levels in the respiratory tract of severe COVID-19 patients [43], cleave sialic acid residues which enhances ROS production and NETosis by inflammatory neutrophils in COVID-19, and these effects can be blocked by the Neu inhibitors oseltamivir or zanamivir (Fig. 1D) [128]. Similarly, the Neu inhibitor peramivir, in combination with an anti-HMGBl antibody, attenuated immune signaling and improved survival in an influenza-induced pneumonia mouse model [129]. In addition to targeting Siglec biology, blocking the TLRs, which act as receptors for both PAMPs and DAMPs, is being studied as a way of tamping down inflammation in several diseases including COVID-19 [130–132]. Additionally, cytokine blockers - for example the anti-IL-6R antibodies tocilizumab (Actemra) and sarilumab (Kevzara) and the anti-IL-6 antibody siltuximab (Sylvanyt) - are also being tested for efficacy in COVID-19 patients. Results from these studies are mixed, and indicate that while anti-IL6 drugs/TLR therapeutics may have a marginal effect on mortality in severe cases of COVID-19, the timing of treatment relative to infection onset appears to be critical for efficacy [133–135]. Furthermore, IL-6 is only one of several proinflammatory mediators released in response to DAMP-mediated inflammation, highlighting the need to identify targets that are higher up in the inflammation cascade, including, perhaps, the DAMPs themselves.

In summary, available data suggest that therapeutic targeting of the pro-inflammatory DAMP-PRR and anti-inflammatory Siglec pathways is promising for the treatment of severe COVID-19, although additional studies are required to validate this approach, to identify therapeutic targets within these pathways that will appropriately balance benefit and risk, and to inform about patient stratification and timing of therapy.

7. Impact of DAMP signaling on other dysregulated processes in COVID-19 and in related disorders

Severe COVID-19 is associated not only with pulmonary symptoms/ARDS, but also with systemic complications including endothelial dysfunction and hypercoagulability [136–138]. Vascular endothelial cells (ECs) express ACE2, making them direct targets for SARS-CoV-2 infection [139–141]. In addition, excessive inflammation associated with COVID-19 ARDS leads to increased pro-inflammatory cytokine signaling and NETosis which results in activation of ECs, and ultimately, endothelial dysfunction. Activated ECs, in turn, increase NET formation, leading to a positive feedback loop that further propagates EC dysfunction [142,143]. This damage to the vascular endothelium causes platelet aggregation, resulting in a prothrombotic phenotype and increased coagulation. In addition, breakdown of the endothelium due to NETosis in the intravascular and perivascular space destabilizes the EC barrier leading to vascular leakage [80,81,143–150]. The mechanism of endothelial damage and vascular leakage in COVID-19 can be in part surmised from studies in sepsis, which show many of the same hallmarks as severe COVID-19. For instance, in sepsis, circulating neutrophils undergo ‘intravascular priming’ coupled to microvascular sequestration, and this increased prevalence of primed neutrophils, as well as neutrophil clustering, correlates with leak and severity of disease [67,151–158]. Vascular damage-induced tissue hypoxia and thrombosis-induced ischemic injury/ROS production also leads to the release of DAMPs, thus fueling the cycle of inflammatory, coagulative, and dysregulated cellular responses. This constant source of DAMPs can impact immunothrombosis and thrombus formation in multiple ways; while DAMPs act on neutrophils to induce formation of NETs, they also act on monocytes to induce expression of tissue factor (TF) [159]. Moreover, different DAMPs can have different effects on immune and non-immune cell subsets, including endothelial cells. For instance, HMGB1 has been shown to induce RAGE-dependent cytokine production in endothelial cells as well as platelets, leading to barrier dysfunction and increased coagulation [160–162], while another DAMP, S100A9, drives thrombus formation and vascular injury, in mouse models [163].

Taken together, existing data highlight the impact of DAMPs on multiple pathophysiological aspects of SARS-CoV-2 infection and emphasize the potential benefits of inhibiting DAMP signaling in severe COVID-19 and related disorders (Fig. 2).

8. Future perspectives

Impaired immune cell function leading to prolonged uncontrolled inflammation is the hallmark of severe COVID-19 pathology. For lack of better options, one common strategy used to control ongoing inflammation is administration of broad-spectrum corticosteroids. Although these drugs ameliorate clinical symptoms in critically ill patients if administered in a timely manner, the resulting immunosuppression can lead to an increased risk of infections. These complications necessitate a careful weighing of the risk–benefit ratio and optimization of dose, timing, and duration when it comes to administration of steroids. Therefore, further research including additional clinical trials will be crucial to evaluate the safety and efficacy of broad interventional therapies targeting inflammation in severe COVID-19.

Like other pathogens, SARS-CoV-2 drives innate immune responses not only through generation of PAMPs that activate PRRs, but also through the generation of endogenous DAMPs. While DAMPs can have a
beneficial effect by contributing to anti-viral inflammatory responses, their continuous release perpetuates overactivation of innate/adaptive immune cells and cytokine storm, leading to several adverse complications such as ARDS, endothelial barrier dysfunction, and increased coagulation. Thus, targeted modulation of DAMP signaling, and associated pathway proteins may be an effective tool in modulating the complex immunological networks and inflammation associated with severe COVID-19. A handful of therapeutics targeting DAMP-mediated signaling have been clinically evaluated in COVID-19 patients, with promising preliminary outcomes. While their development will require additional investigation, targeting DAMPs in COVID-19 and related disorders could address the issues associated with broader anti-inflammatory approaches.

CRediT authorship contribution statement

Upasana Parthasarathy: Conceptualization, Writing – original draft, Writing – review & editing. Roberta Martinelli: Conceptualization, Writing – original draft, Writing – review & editing. Elisabeth H. Vollmann: Writing – original draft. Katharine Best: Writing – original draft. Alex G. Therien: Conceptualization, Writing – original draft, Writing – review & editing, Supervision, Project administration.

Declaration of Competing Interest

All authors are employees of Merck & Co., Inc.

Acknowledgements

Figure illustrations were created using BioRender.com.

References

[1] World Health Organization (WHO) | Coronavirus (COVID-19) Dashboard. https://covid19who.int/ 2021.
[2] N. Stefan, A.L. Birkenfeld, M.B. Schulze, Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. Nature reviews, Endocrinology. 17 (5) (2021) 135–149.
[3] C.H. Sudre, B. Murray, T. Varsavsky, M.S. Graham, R.S. Penfold, R.C. Bowyer, et al., Attributes and predictors of long COVID, Nature medicine. 27 (4) (2021).
[4] The Lancet, Facing up to long COVID, Lancet (London, England) 396 (10266) (2020) 1661, https://doi.org/10.1016/S0140-6736(20)32662-3.
[5] A.D. Proal, M.B. VanElzakker, Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms, Frontiers in microbiology. 12 (2021).
[6] J.H. Kim, F. Marks, J.D. Clemens, Looking beyond COVID-19 vaccine phase 3 trials, Nature medicine. 27 (2) (2021) 205–211.
[7] U.S. Food & Drug Administration (FDA) | COVID-19 Vaccines. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines. 2021.
[8] World Health Organization (WHO) | COVID-19 vaccine tracker and landscape. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. 2021.
[9] National Institute of Health (NIH) | Anti-SARS-CoV-2 Monoclonal Antibodies; COVID-19 Treatment Guidelines. https://www.nih.gov/sites/default/files/clinicalmanagement/covid-19/antibody_products/2021/01/25/20210125.antibody_products.pdf. 2021.
[10] COVID-19 Treatment Guidelines. (2021). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-management.html. 2021.
[11] P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li, C.-L. Huang, H.-D. Chen, J. Chen, Y. Luo, H. Guo, R.-D. Jiang, M.-Q. Lia, Y. Chen, X.-R. Shen, X.i. Wang, X.-S. Zheng, K. Zhao, Q.-J. Chen, F. Deng, L.-L. Liu, B. Yan, F.-X. Zhan, Y.-Y. Wang, G.-F. Xiao, Z.-L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature. 579 (7798) (2020) 270–273.
[12] R. Schafer, G. Spohn, M. Bechtle, D. Bojkova, P.C. Baer, S. Kucl, E. Seifried, S. Cinek, J. Ciztil, Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARS-CoV-2-Infected Cells, Stem cell reports. 16 (3) (2021) 419–427.

Fig. 2. Impact of DAMPs on COVID-19 and associated disorders. Damage-associated molecular patterns (DAMPs) act as a central driver of the feedback loop between cell/tissue damage and hyperactivation of the innate immune response, thus playing a central role in COVID-19 associated complications. SARS-CoV-2 infection and the resulting inflammation can cause epithelial cell death and further release of cytokines and DAMPs that can lead to acute respiratory distress syndrome (ARDS). DAMP-mediated inflammation can also cause damage to the vascular endothelium, platelet activation, thrombosis, and prolonged inflammation resulting in vascular leakage, and hypercoagulation.
[13] M.M. Lamers, J. Beumer, J. van der Vaart, K. Knops, J. Puschhof, H.B.G. Ravelli, J. Paul van Schayck, A.Z. Mykytyn, N.i. Huang, C. B. Lee, A.-S. Lhonneur, V. Saada, A. Stoclin, C. Willekens, F. Pommeret, et al., Endothelial cell infection and endotheliitis in patients with COVID-19. Lancet. 2020;395(10234).

[14] J. Puschhof, K. Knops, J. van der Vaart, F. Meng, S.-L. Zeng, H. Zhu, L. Huang, N.a. Wang, X. Zhou, Z. Chen, Y. Zhao, Neutrophil-lymphotope-taxis as an independent risk factor for mortality in hospitalized patients with COVID-19, The Journal of infection. 81 (1) (2021) e53-61.

[15] X. Zhao, B. Liu, L. Ren, L. Li, Z. Zhong, Y. Xian, J. Li, Guo, J. Yang, Z. Wang, J. Dong, Bo. Liu, X. Zhang, W. Wang, K. He, Q. Jin, M. Li, J. Wu, Heightened innate immune responses in the respiratory tract of COVID-19 Patients, Cell host & microbe. 27 (6) (2020) 883-900.e2.

[16] Y. Su, D. Chen, D. Yuan, C. Lausted, J. Choi, C.L. Dai, et al., Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19, Cell. 183 (6) (2021) 1418-1418.e18.

[17] R.L. Chu, S. Liaskos, S. Chen, A. Gine, S. B Deutsch, et al., COVID-19 immunopathology includes associations with poor prognosis, Nature medicine. 26 (10) (2020).

[18] A. Silvin, N. Chapuis, G. Dansmore, A.-G. Goubet, A. Dubusson, L. Donselaar, A. Chilene, E. van Donselaar, A. Ahles, et al., Macrophage responses in COVID-19 patients: implications for infection and immune response, Microbiology. 5 (49) (2020), https://doi.org/10.1126/sciimmunol.abd1554.

[19] Z. Chen, X. Long, Q. Yao, C. Liu, J. Shi, W. Wang, J. Fan, S. Zhao, C. Xu, G. Paix, et al., The 2019 novel coronavirus (2019-nCoV): Current status and future directions, Frontiers in immunology. 11 (2019), https://doi.org/10.3389/fimmu.2020.00279.

[20] V. Jagannathan, P. Dani, S. Fachinetti, S. Schlickeiser, B. Zhang, et al., Severe COVID-19 is Marked by a Dysregulated Myeloid Cell Compart, Cell. 182 (6) (2020).

[21] T. Cao, X. Sha, J. Tzutsumi, C. Mares, L. J. Feng, W. Huang, J. Zhao, L. Zhao, D. Zhao, J. Zhou, S. Zhang, X. Zeng, Z. Li, X. Chen, Y. Zhao, Neutrophil-lymphotope-taxis as an independent risk factor for mortality in hospitalized patients with COVID-19, The Journal of infection. 81 (1) (2021) e53-61.

[22] J. Xiao, H. Xie, K. Hu, J. Wu, Y. Zhang, M.-M. Wang, T. Wang, Z.-S.Zheng, X. Zeng, X. Ding, H. Nie, Clinical features in 52 patients with COVID-19 who have increased leucocyte count: a retrospective analysis. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical, Microbiology. 39 (12) (2020) 2279-2287.

[23] S. Zhang, Z. Li, X. Chen, L. Zhao, D. Zhao, J. Zhou, S. Zhang, X. Zeng, Z. Li, X. Chen, Y. Zhao, Neutrophil-lymphotope-taxis as an independent risk factor for mortality in hospitalized patients with COVID-19, The Journal of infection. 81 (1) (2021) e53-61.
[157] A. Thijs, L.G. Thijs, Pathogenesis of renal failure in sepsis, Kidney international Supplement. 66 (1998) S34–S37.

[158] T.H. Wyman, A.J. Bjornsen, D.J. Elzi, C.W. Smith, K.M. England, M. Kelher, C. C. Silliman, A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release, American journal of physiology Cell physiology. 283 (6) (2002) C1592–C1602.

[159] T. Ito, PAMPs and DAMPs as triggers for DIC, Journal of intensive care. 2 (1) (2014), https://doi.org/10.1186/s40560-014-0065-0.

[160] Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101(7).

[161] C.J. Treutiger, G.E. Mullins, A.-S.- M. Johansson, A. Rouhiainen, H.M.E. Rauvola, H. Erlandsson-Harris, U. Andersson, H. Yang, K.J. Tracey, J. Andersson, J.E. W. Palmblad, High mobility group 1 B-box mediates activation of human endothelium, Journal of internal medicine. 254 (4) (2003) 375–385.

[162] I. Ahrens, Y.-C. Chen, D. Topcic, M. Bode, D. Haenel, C.E. Hagemeyer, H. Seeba, D. Duerschmied, N. Bassler, K.A. Jandeleit-Dahm, M.J. Sweet, A. Agrotis, A. Bobik, K. Peter, HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi, Thrombosis and haemostasis. 114 (11) (2015) 994–1003.

[163] T. Kawano, M. Shimamura, H. Nakagami, T. Iso, H. Koriyama, S. Takeda, K. Baba, T. Sasaki, M. Sakaguchi, R. Morishita, H. Mochizuki, Therapeutic Vaccine Against S100A9 (S100 Calcium-Binding Protein A9) Inhibits Thrombosis Without Increasing the Risk of Bleeding in Ischemic Stroke in Mice. Hypertension (Dallas, Tex 72 (6) (2018) 1355–1364.